Rompianesi Gianluca, Montalti Roberto, Cautero Nicola, De Ruvo Nicola, Stafford Anthony, Bronzoni Carolina, Ballarin Roberto, De Pietri Lesley, Di Benedetto Fabrizio, Gerunda Giorgio E
Liver Transplant Centre, Azienda Ospedaliero-Universitaria di Modena Policlinico, Modena, Italy.
Institute of Liver Studies, King's College Hospital, London, UK.
Transpl Int. 2015 Jul;28(7):864-9. doi: 10.1111/tri.12564. Epub 2015 Apr 6.
Neurological complications (NCs) can frequently and significantly affect morbidity and mortality of liver transplant (LT) recipients. We analysed incidence, risk factors, outcome and impact of the immunosuppressive therapy on NC development after LT. We analysed 478 LT in 440 patients, and 93 (19.5%) were followed by NCs. The average LOS was longer in patients experiencing NCs. The 1-, 3- and 5-year graft survival and patient survival were similar in patients with or without a NC. Multivariate analysis showed the following as independent risk factors for NC: a MELD score ≥20 (OR = 1.934, CI = 1.186-3.153) and an immunosuppressive regimen based on calcineurin inhibitors (CNIs) (OR = 1.669, CI = 1.009-2.760). Among patients receiving an everolimus-based immunosuppression, the 7.1% developed NCs, vs. the 16.9% in those receiving a CNI (P = 0.039). There was a 1-, 3- and 5-year NC-free survival of 81.7%, 81.1% and 77.7% in patients receiving a CNI-based regimen and 95.1%, 93.6% and 92.7% in those not receiving a CNI-based regimen (P < 0.001). In patients undergoing a LT and presenting with nonmodifiable risk factors for developing NCs, an immunosuppressive regimen based on CNIs is likely to result in a higher rate of NCs compared to mTOR inhibitors.
神经并发症(NCs)会频繁且显著地影响肝移植(LT)受者的发病率和死亡率。我们分析了肝移植后免疫抑制治疗对NCs发生的发生率、危险因素、结局及影响。我们分析了440例患者的478例肝移植情况,其中93例(19.5%)出现了NCs。发生NCs的患者平均住院时间更长。有或无NCs的患者1年、3年和5年的移植物存活率及患者存活率相似。多因素分析显示以下为NCs的独立危险因素:终末期肝病模型(MELD)评分≥20(比值比[OR]=1.934,可信区间[CI]=1.186 - 3.153)以及基于钙调神经磷酸酶抑制剂(CNIs)的免疫抑制方案(OR = 1.669,CI = 1.009 - 2.760)。在接受依维莫司为基础的免疫抑制治疗的患者中,7.1%发生了NCs,而接受CNI治疗的患者中这一比例为16.9%(P = 0.039)。接受基于CNI方案的患者1年、3年和5年无NCs生存率分别为81.7%、81.1%和77.7%,未接受基于CNI方案的患者分别为95.1%、93.6%和92.7%(P < 0.001)。在接受肝移植且存在发生NCs不可改变危险因素的患者中,与mTOR抑制剂相比,基于CNIs的免疫抑制方案可能导致更高的NCs发生率。